GlassScriptPhysician profile
Kuldip Singh
NPI 1073074910
$428.18
in general payments reported to CMS, 2019-2025
15 companies · $282 in 2025
The $282 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $146 · 2025: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $428.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $158.06 | 2024-2025 | Tagrisso |
| Takeda Pharmaceuticals U.S.A., INC. | $26.80 | 2025 | Iclusig |
| Azurity Pharmaceuticals, INC. | $22.10 | 2025 | Danziten, Vivimusta |
| Janssen Biotech, INC. | $21.32 | 2025 | Erleada |
| Taiho Oncology, INC. | $21.32 | 2024 | |
| Lilly USA, LLC | $21.06 | 2025 | Jaypirca, Verzenio |
| Beone Medicines USA, INC. | $20.95 | 2025 | Brukinsa |
| Genzyme Corporation | $20.05 | 2025 | |
| Glaxosmithkline, LLC. | $19.94 | 2025 | Jemperli, Zejula |
| Merck Sharp & Dohme LLC | $19.39 | 2025 | Lynparza, Keytruda Qlex, Keytruda |
| Pharmacosmos Therapeutics INC. | $18.51 | 2025 | Monoferric |
| Regeneron Healthcare Solutions, INC. | $15.76 | 2025 | Libtayo |
| Adaptive Biotechnologies Corporation | $14.43 | 2025 | Clonoseq |
| Alexion Pharmaceuticals, INC. | $14.33 | 2025 | Ultomiris |
| Geron Corporation | $14.16 | 2025 | Rytelo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kuldip Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.